


Targeting Molecular Subtypes of  
Pancreatic Cancer

Our understanding of the molecular pathology of pancreatic cancer has advanced substantially over the past decade. Model systems that permit manipulation and therapeutic testing are as good as many other cancer types, yet progress continues to be slow. Clearly, the therapeutic development paths that have been successful in many other cancer types are not providing the same benefits in pancreatic cancer. What do we need to do differently? This presentation examines the current state of play of knowledge of the molecular pathology of pancreatic cancer and its relevance to therapeutic development. The opportunities and the challenges that are emerging as the result of our increased understanding of the disease, and what changes in overall approaches may accelerate progress including the generation, characterization and manipulation of next-generation model systems including patient-derived models.

**Dr. Andrew Biankin**

Wolfson Wohl Cancer Research Centre  
Institute of Cancer Sciences  
University of Glasgow

Host: Dr. Lincoln Stein

**Date:** Tuesday February 20<sup>th</sup>, 2018

**Time:** 1:30 PM

**Place:** CCBR Red Seminar Room; 160  
College St